Actively Recruiting
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study
Led by icometrix · Updated on 2025-12-12
7000
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
Sponsors
I
icometrix
Lead Sponsor
C
Charite University, Berlin, Germany
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are gathering and analyzing data to create AI-based models aimed at improving diagnosis and prognosis for people with Multiple Sclerosis (MS) and related disorders such as NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome, and Clinically Isolated Syndrome. This observational study focuses on developing tools that support personalized treatment decisions and monitoring disease progression in real-world settings. The study collects retrospective real-world clinical data from six participating clinical centers and data from control groups of relevant clinical trials from four pharmaceutical partners. By harmonizing this data into a centralized database, the study aims to build MRI-based tools and AI models for predicting brain changes, disease progression, and treatment responses in individual patients. Participants contribute data through existing medical records, with no new treatments or interventions. Researchers evaluate data completeness, accuracy, and representativeness, including MRI compliance and quality control. Outcomes measured include data contributions from each site, disease history completeness, and disability assessments over four years. The study will monitor data over time to ensure uniformity and develop tools to better track and understand MS progression.
CONDITIONS
Brief Title
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have a confirmed diagnosis of MS, NMOSD, MOGAD, CIS, or RIS.
- Patient or legal representative has signed informed consent for secondary use of data, or data use is approved by an ethical committee.
- Participants are 18 years or older.
You will not qualify if you...
- Patients under 18 years of age.
- Patients deemed unsuitable for participation by the investigator or steering committee for unspecified reasons.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to confirm eligibility and consent
Duration - Up to 4 years
Participants who undergo routine care are observed through the collection and analysis of retrospective clinical and MRI data to monitor disease progression and treatment history.
No additional visits; data is collected retrospectively from existing records
Trial Site Locations
Total: 3 locations
1
General University Hospital Prague
Prague, Praha 2, Czechia, 128 00
Actively Recruiting
2
Katholisches Klinikum Bochum - St. Joseph-Hospital
Bochum, Bochum, Germany, 44791
Actively Recruiting
3
ERC Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, Germany, 131256
Actively Recruiting
Research Team
D
Diana M Sima, PhD
V
Vincenzo Anania
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here